Quick Answer
REGENEREX PHARMA, INC. reported Net Income Loss of -$2.53 million for the year ending 2025.
- REGENEREX PHARMA, INC. showed an increase of +28.7% in Net Income Loss from 2024 to 2025.
- This data is from REGENEREX PHARMA, INC.'s annual report (Form 10-K), filed with the SEC on June 30, 2025.
- XBRL data for this metric is available from 2009 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2009 to 2025), REGENEREX PHARMA, INC.'s Net Income Loss has declined by 39,453.0%.
- Historical annual values: Fiscal year 2025: -$2.53 million | Fiscal year 2024: -$3.54 million | Fiscal year 2023: -$137.3 thousand | Fiscal year 2022: -$195.6 thousand | Fiscal year 2021: -$353.8 thousand | Fiscal year 2020: $111.6 thousand | Fiscal year 2019: -$93.6 thousand | Fiscal year 2018: -$49.7 thousand | Fiscal year 2017: -$2.6 thousand | Fiscal year 2014: $859.8 thousand | Fiscal year 2013: -$995.5 thousand | Fiscal year 2012: -$659.7 thousand | Fiscal year 2011: -$212.1 thousand | Fiscal year 2010: -$27.4 thousand | Fiscal year 2009: -$6.4 thousand.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: